Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
21 Juni 2021
Regulatory reform for software-based consumer health - Can rules keep up with reality?
2 Juni 2021
New Zoning Initiatives to Promote Public Health
The Department of City Planning (DCP) has proposed a text amendment to modify regulations relating to gyms, spas, and licensed massage therapy and other …
26 Mai 2021
Australian Consumer Law marks 10 years with some large penalties
13 April 2021
Pharmaceutical patent term extensions: federal court hears challenge to “absurd” Australian patent office ruling
13 April 2021
NAIC Considers PBM Regulation; Additional Requirements Possibly on Tap
Pharmacy benefit managers (PBMs) should consider the implications of a model law making its way through the National Association of Insurance …
11 März 2021
A ‘new normal’ when it comes to the TGA regulation of medical devices?
8 März 2021
Asia Pacific M&A Review 2021
26 Februar 2021
Judicial review and the life sciences and health sectors
24 Februar 2021
2020 Australian IPO Review: Key themes
24 Februar 2021
2020 Australian IPO Review: IPOs by the numbers
16 Februar 2021
Patent and Pharma update, February 2021
8 Februar 2021
Healthcare as an Infrastructure asset
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane